EMEA-001407-PIP02-15-M02

Key facts

Invented name
Opdivo
Active substance
nivolumab
Therapeutic area
Oncology
Decision number
P/0050/2018
PIP number
EMEA-001407-PIP02-15-M02
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
  • Treatment of malignant neoplasms of the central nervous system
  • Treatment of malignant neoplasms of lymphoid tissue
Route(s) of administration
Intravenous use
Contact for public enquiries
Bristol-Myers Squibb Pharma EEIG
Tel. +44 (0)1895 523740
E-mail: medical.information@bms.com
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating